Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
37
TRGNF Quote, Financials, Valuation and Earnings
Last price:
$1.00
Seasonality move
:
2516.32%
Day range:
$1.00 - $1.00
52-week range:
$0.70 - $1.59
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1,122.44x
P/B ratio:
0.72x
Volume:
--
Avg. volume:
--
1-year change:
-37.11%
Market cap:
$132.3M
Revenue:
$37.9K
EPS (TTM):
-$0.30
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
TRGNF
Transgene SA
|
-- | -- | -- | -- | -- |
|
ADOCY
Adocia SA
|
-- | -- | -- | -- | -- |
|
CLLS
Cellectis SA
|
$12.7M | -$0.11 | 24.25% | -56.58% | $7.25 |
|
DBVT
DBV Technologies SA
|
$1.3M | -$0.22 | -- | -86.12% | $40.16 |
|
GNFTF
Genfit SA
|
$33.6M | -- | -- | -- | -- |
|
NICXF
Nicox SA
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
TRGNF
Transgene SA
|
$1.00 | -- | $132.3M | -- | $0.00 | 0% | 1,122.44x |
|
ADOCY
Adocia SA
|
$11.80 | -- | $231.1M | -- | $0.00 | 0% | 17.36x |
|
CLLS
Cellectis SA
|
$4.02 | $7.25 | $404.4M | -- | $0.00 | 0% | 5.00x |
|
DBVT
DBV Technologies SA
|
$21.52 | $40.16 | $1.2B | -- | $0.00 | 0% | -- |
|
GNFTF
Genfit SA
|
$9.00 | -- | $450.3M | 49.25x | $0.00 | 0% | 9.90x |
|
NICXF
Nicox SA
|
$0.30 | -- | $24.3M | -- | $0.00 | 0% | 5.89x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
TRGNF
Transgene SA
|
-- | 0.532 | -- | 1.42x |
|
ADOCY
Adocia SA
|
-493.39% | 0.000 | -- | 0.97x |
|
CLLS
Cellectis SA
|
54.27% | 0.329 | 41.7% | 1.35x |
|
DBVT
DBV Technologies SA
|
23.24% | -3.992 | 5.85% | 1.41x |
|
GNFTF
Genfit SA
|
-- | -0.368 | -- | -- |
|
NICXF
Nicox SA
|
54.24% | 0.454 | 91.41% | 1.21x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
TRGNF
Transgene SA
|
-- | -- | -182.92% | -182.92% | -- | -- |
|
ADOCY
Adocia SA
|
-- | -- | -- | -- | -- | -- |
|
CLLS
Cellectis SA
|
$30M | $5.9M | -15.69% | -31.08% | 16.76% | -$4M |
|
DBVT
DBV Technologies SA
|
-$4.3M | -$36.9M | -211.46% | -280.59% | -- | -$32.5M |
|
GNFTF
Genfit SA
|
-- | -- | -- | -- | -- | -- |
|
NICXF
Nicox SA
|
-- | -- | -24.01% | -43.13% | -- | -- |
Transgene SA vs. Competitors
-
Which has Higher Returns TRGNF or ADOCY?
Adocia SA has a net margin of -- compared to Transgene SA's net margin of --. Transgene SA's return on equity of -182.92% beat Adocia SA's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital TRGNFTransgene SA-- -- -$660.3K ADOCYAdocia SA-- -- -$1.3M -
What do Analysts Say About TRGNF or ADOCY?
Transgene SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Adocia SA has an analysts' consensus of -- which suggests that it could fall by --. Given that Transgene SA has higher upside potential than Adocia SA, analysts believe Transgene SA is more attractive than Adocia SA.
Company Buy Ratings Hold Ratings Sell Ratings TRGNFTransgene SA0 0 0 ADOCYAdocia SA0 0 0 -
Is TRGNF or ADOCY More Risky?
Transgene SA has a beta of 42.864, which suggesting that the stock is 4186.443% more volatile than S&P 500. In comparison Adocia SA has a beta of -0.184, suggesting its less volatile than the S&P 500 by 118.359%.
-
Which is a Better Dividend Stock TRGNF or ADOCY?
Transgene SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Adocia SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Transgene SA pays -- of its earnings as a dividend. Adocia SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TRGNF or ADOCY?
Transgene SA quarterly revenues are $105.2K, which are larger than Adocia SA quarterly revenues of --. Transgene SA's net income of -- is lower than Adocia SA's net income of --. Notably, Transgene SA's price-to-earnings ratio is -- while Adocia SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Transgene SA is 1,122.44x versus 17.36x for Adocia SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TRGNFTransgene SA1,122.44x -- $105.2K -- ADOCYAdocia SA17.36x -- -- --
-
Which has Higher Returns TRGNF or CLLS?
Cellectis SA has a net margin of -- compared to Transgene SA's net margin of 1.68%. Transgene SA's return on equity of -182.92% beat Cellectis SA's return on equity of -31.08%.
Company Gross Margin Earnings Per Share Invested Capital TRGNFTransgene SA-- -- -$660.3K CLLSCellectis SA85.76% $0.01 $219.7M -
What do Analysts Say About TRGNF or CLLS?
Transgene SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Cellectis SA has an analysts' consensus of $7.25 which suggests that it could grow by 80.35%. Given that Cellectis SA has higher upside potential than Transgene SA, analysts believe Cellectis SA is more attractive than Transgene SA.
Company Buy Ratings Hold Ratings Sell Ratings TRGNFTransgene SA0 0 0 CLLSCellectis SA2 2 0 -
Is TRGNF or CLLS More Risky?
Transgene SA has a beta of 42.864, which suggesting that the stock is 4186.443% more volatile than S&P 500. In comparison Cellectis SA has a beta of 2.833, suggesting its more volatile than the S&P 500 by 183.275%.
-
Which is a Better Dividend Stock TRGNF or CLLS?
Transgene SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cellectis SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Transgene SA pays -- of its earnings as a dividend. Cellectis SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TRGNF or CLLS?
Transgene SA quarterly revenues are $105.2K, which are smaller than Cellectis SA quarterly revenues of $35M. Transgene SA's net income of -- is lower than Cellectis SA's net income of $586.4K. Notably, Transgene SA's price-to-earnings ratio is -- while Cellectis SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Transgene SA is 1,122.44x versus 5.00x for Cellectis SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TRGNFTransgene SA1,122.44x -- $105.2K -- CLLSCellectis SA5.00x -- $35M $586.4K
-
Which has Higher Returns TRGNF or DBVT?
DBV Technologies SA has a net margin of -- compared to Transgene SA's net margin of --. Transgene SA's return on equity of -182.92% beat DBV Technologies SA's return on equity of -280.59%.
Company Gross Margin Earnings Per Share Invested Capital TRGNFTransgene SA-- -- -$660.3K DBVTDBV Technologies SA-- -$1.21 $68.9M -
What do Analysts Say About TRGNF or DBVT?
Transgene SA has a consensus price target of --, signalling downside risk potential of --. On the other hand DBV Technologies SA has an analysts' consensus of $40.16 which suggests that it could grow by 86.61%. Given that DBV Technologies SA has higher upside potential than Transgene SA, analysts believe DBV Technologies SA is more attractive than Transgene SA.
Company Buy Ratings Hold Ratings Sell Ratings TRGNFTransgene SA0 0 0 DBVTDBV Technologies SA4 0 1 -
Is TRGNF or DBVT More Risky?
Transgene SA has a beta of 42.864, which suggesting that the stock is 4186.443% more volatile than S&P 500. In comparison DBV Technologies SA has a beta of -0.978, suggesting its less volatile than the S&P 500 by 197.819%.
-
Which is a Better Dividend Stock TRGNF or DBVT?
Transgene SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Transgene SA pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TRGNF or DBVT?
Transgene SA quarterly revenues are $105.2K, which are larger than DBV Technologies SA quarterly revenues of --. Transgene SA's net income of -- is lower than DBV Technologies SA's net income of -$33M. Notably, Transgene SA's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Transgene SA is 1,122.44x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TRGNFTransgene SA1,122.44x -- $105.2K -- DBVTDBV Technologies SA-- -- -- -$33M
-
Which has Higher Returns TRGNF or GNFTF?
Genfit SA has a net margin of -- compared to Transgene SA's net margin of --. Transgene SA's return on equity of -182.92% beat Genfit SA's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital TRGNFTransgene SA-- -- -$660.3K GNFTFGenfit SA-- -- -- -
What do Analysts Say About TRGNF or GNFTF?
Transgene SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Genfit SA has an analysts' consensus of -- which suggests that it could fall by --. Given that Transgene SA has higher upside potential than Genfit SA, analysts believe Transgene SA is more attractive than Genfit SA.
Company Buy Ratings Hold Ratings Sell Ratings TRGNFTransgene SA0 0 0 GNFTFGenfit SA0 0 0 -
Is TRGNF or GNFTF More Risky?
Transgene SA has a beta of 42.864, which suggesting that the stock is 4186.443% more volatile than S&P 500. In comparison Genfit SA has a beta of 0.130, suggesting its less volatile than the S&P 500 by 86.956%.
-
Which is a Better Dividend Stock TRGNF or GNFTF?
Transgene SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Genfit SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Transgene SA pays -- of its earnings as a dividend. Genfit SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TRGNF or GNFTF?
Transgene SA quarterly revenues are $105.2K, which are larger than Genfit SA quarterly revenues of --. Transgene SA's net income of -- is lower than Genfit SA's net income of --. Notably, Transgene SA's price-to-earnings ratio is -- while Genfit SA's PE ratio is 49.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Transgene SA is 1,122.44x versus 9.90x for Genfit SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TRGNFTransgene SA1,122.44x -- $105.2K -- GNFTFGenfit SA9.90x 49.25x -- --
-
Which has Higher Returns TRGNF or NICXF?
Nicox SA has a net margin of -- compared to Transgene SA's net margin of --. Transgene SA's return on equity of -182.92% beat Nicox SA's return on equity of -43.13%.
Company Gross Margin Earnings Per Share Invested Capital TRGNFTransgene SA-- -- -$660.3K NICXFNicox SA-- -- $46.8M -
What do Analysts Say About TRGNF or NICXF?
Transgene SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Nicox SA has an analysts' consensus of -- which suggests that it could fall by --. Given that Transgene SA has higher upside potential than Nicox SA, analysts believe Transgene SA is more attractive than Nicox SA.
Company Buy Ratings Hold Ratings Sell Ratings TRGNFTransgene SA0 0 0 NICXFNicox SA0 0 0 -
Is TRGNF or NICXF More Risky?
Transgene SA has a beta of 42.864, which suggesting that the stock is 4186.443% more volatile than S&P 500. In comparison Nicox SA has a beta of -0.043, suggesting its less volatile than the S&P 500 by 104.266%.
-
Which is a Better Dividend Stock TRGNF or NICXF?
Transgene SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nicox SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Transgene SA pays -- of its earnings as a dividend. Nicox SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TRGNF or NICXF?
Transgene SA quarterly revenues are $105.2K, which are larger than Nicox SA quarterly revenues of --. Transgene SA's net income of -- is lower than Nicox SA's net income of --. Notably, Transgene SA's price-to-earnings ratio is -- while Nicox SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Transgene SA is 1,122.44x versus 5.89x for Nicox SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TRGNFTransgene SA1,122.44x -- $105.2K -- NICXFNicox SA5.89x -- -- --
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
50
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 38x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Sell
37
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
59
SEZL alert for Feb 27
Sezzle, Inc. [SEZL] is down 15.34% over the past day.
Buy
83
GCT alert for Feb 27
GigaCloud Technology, Inc. [GCT] is down 7.22% over the past day.
Buy
62
LMAT alert for Feb 27
LeMaitre Vascular, Inc. [LMAT] is down 5.48% over the past day.
